Evotec (EVT) Stock Overview
Operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
EVT Community Fair Values
Create NarrativeSee what 38 others think this stock is worth. Follow their fair value or set your own to get alerts.
Evotec SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €7.41 |
| 52 Week High | €10.62 |
| 52 Week Low | €5.06 |
| Beta | 1.09 |
| 1 Month Change | 5.89% |
| 3 Month Change | 15.88% |
| 1 Year Change | -14.80% |
| 3 Year Change | -71.57% |
| 5 Year Change | -70.49% |
| Change since IPO | -52.94% |
Recent News & Updates
Recent updates
Pharmaceutical Collaborations And Cost Savings Will Drive Excellence
Strengthened partnerships with major pharma companies and a focus on biologics manufacturing are expected to boost Evotec's revenue and earnings.Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price
Nov 10
A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb
Nov 05Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price
Aug 17Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 08We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt
Aug 03Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues
Apr 10These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well
Mar 05A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price
Jan 09We Think Evotec (ETR:EVT) Can Stay On Top Of Its Debt
Oct 05Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet
Jun 28Is There An Opportunity With Evotec SE's (ETR:EVT) 37% Undervaluation?
May 14Does Evotec (ETR:EVT) Have A Healthy Balance Sheet?
Feb 25Shareholder Returns
| EVT | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 2.9% | -5.6% | -0.8% |
| 1Y | -14.8% | -21.0% | 18.4% |
Return vs Industry: EVT exceeded the German Life Sciences industry which returned -20.7% over the past year.
Return vs Market: EVT underperformed the German Market which returned 16.9% over the past year.
Price Volatility
| EVT volatility | |
|---|---|
| EVT Average Weekly Movement | 8.9% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: EVT's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: EVT's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 4,766 | Christian Wojczewski | www.evotec.com |
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic diseases; and animal and women health.
Evotec SE Fundamentals Summary
| EVT fundamental statistics | |
|---|---|
| Market cap | €1.32b |
| Earnings (TTM) | -€206.98m |
| Revenue (TTM) | €788.22m |
Is EVT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVT income statement (TTM) | |
|---|---|
| Revenue | €788.22m |
| Cost of Revenue | €680.87m |
| Gross Profit | €107.35m |
| Other Expenses | €314.33m |
| Earnings | -€206.98m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 13, 2025
| Earnings per share (EPS) | -1.17 |
| Gross Margin | 13.62% |
| Net Profit Margin | -26.26% |
| Debt/Equity Ratio | 52.5% |
How did EVT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/17 02:10 |
| End of Day Share Price | 2025/07/17 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Evotec SE is covered by 30 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrick Trucchio | Berenberg |
| Michael Ryskin | BofA Global Research |
| Peter Verdult | Citigroup Inc |